Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Children with juvenile idiopathic arthritis (JIA) who are overweight or obese clear adalimumab about 30% faster than their peers, leading to lower drug levels and less improvement in joint disease activity. A study presented at ACR Convergence 2026 found that kids weighing over 30 kg are especially affected by the current dosing cap. Researchers say it's time to rethink how adalimumab is dosed based on body size.
Children with juvenile idiopathic arthritis (JIA) who carry extra weight may not be getting enough of their medication to see real results. A prospective, multicenter study presented at ACR Convergence 2026 found that kids with overweight or obesity clear adalimumab roughly 30% faster than those at a healthy weight — meaning the drug exits their system before it can do its job.
The study enrolled 36 children (aged 2+) with various JIA subtypes across 8 CARRA centers. Pharmacokinetic modeling and dosing simulations revealed that as body weight climbed, simulated adalimumab trough concentrations dropped — a trend that became especially pronounced in children weighing more than 30 kg, the current dosing cap threshold.
The clinical impact was notable: children with overweight or obesity showed a mean reduction of just 0.4 points on the disease activity score (cJADAS10) versus 9 points in their normal-weight peers over approximately 6 months.
By the Numbers:
Why it matters: Standard weight-based dosing caps may leave heavier children with JIA undertreated. The findings make a compelling case for body size–tailored adalimumab regimens — though researchers note the results need validation in larger cohorts before clinical guidelines change.
